• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears Mallya smart insulin pen device from Biocorp

December 7, 2022 By Sean Whooley

Biocorp Mallya smart insulin pen
The Mallya smart insulin pen device. [Image from Biocorp]
Biocorp announced today that it received FDA 510(k) clearance to market its Mallya smart medical device that connects insulin pens.

Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects nad records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection.

Biocorp said in a news release that clearance makes Mallya the first system approved in the U.S. capable of automatically connecting different types of insulin and GLP-1 drugs. This includes an initial version of Mallya compatible with Sanofi’s Solostar pen injectors.

Mallya holds CE mark approval in Europe as a Class IIb medical device. It offers the ability to connect to different types of injection pens. It can allow patients to achieve multitherapy, notably with the use of basal and rapid insulin.

Biocorp said it already signed partnerships with multiple leaders in the diabetes space. That list includes Novo Nordisk, Sanofi and Roche Diabetes Care.

The company noted that FDA clearance helps it accelerate the submission of Mallya’s future generations. That includes the diabetes field and other therapeutic areas.

“This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world’s largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya’s services,” said Biocorp CEO Eric Dessertenne. “This regulatory milestone will have a positive impact on our sales outlook in 2023 and positions BIOCORP as a leader in the field of smart pens.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: biocorp, FDA

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS